Favre R, Hecquet B
Institut J. Paoli-I, Calmettes, Service d'Hématologie et de Chimiothérapie, Marseille, France.
Pathol Biol (Paris). 1988 Dec;36(10):1199-203.
During the study of chemotherapy responsiveness of twenty nine human tumors by 6 day subrenal capsule assay (SRCA), we measured, after cisplatinum regimen, the total platinum in human tumor implants and in mice plasma and renal tissue. The plasmatic (m = 0.36 +/- 0.13 microgram/ml) and renal (m = 16.1 +/- 6.4 ng/ml) total platinum concentrations are correlated. In human tumor implants the total platinum is measurable in only ten cases (above the minimum value of 7 ng/mg). There are no correlation between the tumor total platinum concentrations and the tumor cisplatinum chemosensitivity. The study is an example of anti-cancer drugs dosage in SRCA.
在通过6天肾包膜下接种法(SRCA)对29个人类肿瘤的化疗反应性进行研究期间,我们在顺铂治疗方案后测量了人类肿瘤植入物、小鼠血浆和肾组织中的总铂含量。血浆(m = 0.36 +/- 0.13微克/毫升)和肾脏(m = 16.1 +/- 6.4纳克/毫升)中的总铂浓度具有相关性。在人类肿瘤植入物中,仅在10例中可检测到总铂(高于7纳克/毫克的最小值)。肿瘤总铂浓度与肿瘤顺铂化疗敏感性之间没有相关性。该研究是SRCA中抗癌药物剂量研究的一个实例。